STOCK TITAN

BioRestorative Therapies, Inc. - BRTX STOCK NEWS

Welcome to our dedicated page for BioRestorative Therapies news (Ticker: BRTX), a resource for investors and traders seeking the latest updates and insights on BioRestorative Therapies stock.

BioRestorative Therapies, Inc. (NASDAQ: BRTX) is a cutting-edge biotechnology company based in the United States, dedicated to developing regenerative medicine products and therapies using cell and tissue protocols, particularly involving adult stem cells. The company’s core focuses are its Disc/Spine Program and Metabolic Program.

In the Disc/Spine Program, their lead cell therapy candidate, BRTX-100, is formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow. This innovative treatment is designed for the non-surgical management of protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease. BRTX-100 undergoes a meticulous production process, starting from the collection of a patient’s bone marrow, followed by the isolation and culturing of stem cells, and finally cryopreserving these cells. The therapy involves injecting BRTX-100 into the patient's damaged disc, offering hope for patients whose pain has not been alleviated by other non-invasive treatments.

The Metabolic Program focuses on developing cell-based therapies to combat obesity and metabolic disorders using brown adipose-derived stem cells. This innovative approach aims to generate brown adipose tissue to help address these widespread health issues.

BioRestorative Therapies is also venturing into the rapidly growing bio-cosmeceutical market. The company recently signed a five-year exclusive supply agreement with Cartessa Aesthetics, LLC, a prominent North American aesthetics company. This partnership aims to introduce proprietary cell-based innovations to the aesthetics market, leveraging both BioRestorative’s expertise in cell-based biologics and Cartessa’s strong market presence.

Financially, BioRestorative is strong, ending 2023 with around $11.1 million in cash and cash equivalents, and an additional $7.6 million from a recent private placement. This solid financial standing, combined with expected revenues from its new commercial products, allows the company to pursue further advancements in their clinical and preclinical pipelines, including their BRTX-100 and ThermoStem® programs.

For more information, visit BioRestorative Therapies or contact Investor Relations at ir@biorestorative.com.

Rhea-AI Summary

BioRestorative Therapies has completed certification of its clinical grade cell therapy manufacturing facility in Melville, NY, which meets FDA and EMA standards. This facility supports the ongoing Phase 2 trial of BRTX-100, targeting chronic lumbar disc disease. The trial includes up to 99 patients across 15 sites and is set to begin patient treatment in Q2 2022. The facility enhances quality control for BRTX-100 production, critical for the upcoming clinical trial. BioRestorative's focus remains on developing therapies using adult stem cells.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.18%
Tags
none
-
Rhea-AI Summary

BioRestorative Therapies (NASDAQ: BRTX) has announced a research collaboration with Dr. Tore Bengtsson from Stockholm University to explore brown fat tissue's biology and its role in heat production. The collaboration aims to enhance understanding of the thermogenic response of BioRestorative's proprietary cell lines. This research is expected to benefit the company's ThermoStem program, which targets obesity and metabolic disorders using brown adipose-derived stem cells to promote caloric burning and improve metabolic health.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.68%
Tags
none
-
Rhea-AI Summary

BioRestorative Therapies (NASDAQ: BRTX) announced a significant milestone with the U.S. Patent and Trademark Office granting a notice of allowance for a key patent related to its BRTX-100 clinical program.

This patent covers methods for preparing a stem cell population aimed at treating chronic lumbar disc disease, enhancing the therapeutic viability of the cells in low oxygen environments typical of damaged discs. CEO Lance Alstodt emphasized this development as crucial for fortifying the company’s intellectual property and clinical advancement in a promising market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.65%
Tags
none
Rhea-AI Summary

BioRestorative Therapies has announced the initiation of site selection for its Phase 2 clinical trial targeting chronic lumbar disc disease with BRTX-100. This double-blind, randomized trial will evaluate the safety and preliminary efficacy of an intradiscal injection in up to 99 patients across 15 centers in the U.S. The company emphasizes selecting sites with proven experience in similar studies to ensure adherence to good clinical practice standards.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.02%
Tags
-
Rhea-AI Summary

BioRestorative Therapies announced its uplisting to Nasdaq and will celebrate by ringing the closing bell on February 7, 2022. CEO Lance Alstodt emphasized the company's commitment to validating its technology through regulatory processes, aiming to lead in the cellular therapy market. Over the past decade, BioRestorative has established a strong foundation in science and clinical translation while planning to expand its therapeutic pipeline. The company's core programs focus on BRTX-100 for disc/spine disease and ThermoStem for metabolic disorders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.02%
Tags
none
-
Rhea-AI Summary

BioRestorative Therapies, Inc. (NASDAQ: BRTX) announced a notice of allowance from the Japanese Patent Office for a patent linked to its ThermoStem® Program. This notice, issued on January 26, 2022, covers implantable three-dimensional scaffolds and brown adipocytes derived from human stem cells, aimed at delivering metabolically active cells for treating metabolic disorders. CEO Lance Alstodt emphasized this strengthens their global patent portfolio and highlights ThermoStem® as a viable treatment for diabetes and obesity, addressing significant unmet medical needs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.96%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.56%
Tags
none
-
Rhea-AI Summary

BioRestorative Therapies (NASDAQ:BRTX) has appointed Robert Paccasassi as Vice President of Quality Assurance/Regulatory Compliance. With over 25 years of experience in biotech and quality systems, he will oversee quality initiatives as the company begins patient enrollment for a Phase 2 clinical trial targeting chronic lumbar disc disease. Paccasassi’s past roles include significant positions at Merck KGaA, Regeneron, Millennium, and Biogen Idec. This leadership appointment aims to enhance the company's compliance and quality control in its stem cell therapy programs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.5%
Tags
management
-
Rhea-AI Summary

BioRestorative Therapies (BRTX) will present a corporate overview at the H.C. Wainwright BioConnect 2022 Conference, scheduled virtually from January 10-13, 2022. CEO Lance Alstodt will lead a pre-recorded presentation available starting January 10 at 7 a.m. ET. Attendees can access the link for the presentation here. The presentation will also be archived for 30 days on the company’s website. BRTX focuses on stem cell-based treatments, including the brtxDISC™ program for spine disease and the ThermoStem® program targeting metabolic disorders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.56%
Tags
conferences
Rhea-AI Summary

BioRestorative Therapies announced a Phase I STTR grant of $256,000 from the NIH to evaluate the therapeutic effects of its hypoxic cultured bone marrow-derived stem cells (BRTX-100) with a novel PEG-peptide hydrogel. This collaboration with Dr. Lori Setton aims to optimize therapeutic delivery methods. Successful completion of this phase could lead to applications for Phase II funding, potentially reaching $1 million. The grant demonstrates recognition of BioRestorative's innovative approach to stem cell therapies, particularly in treating chronic lower back pain.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.85%
Tags
none

FAQ

What is the current stock price of BioRestorative Therapies (BRTX)?

The current stock price of BioRestorative Therapies (BRTX) is $1.55 as of December 20, 2024.

What is the market cap of BioRestorative Therapies (BRTX)?

The market cap of BioRestorative Therapies (BRTX) is approximately 9.9M.

What does BioRestorative Therapies, Inc. specialize in?

BioRestorative Therapies, Inc. specializes in developing regenerative medicine products and therapies using adult stem cells.

What are the main programs developed by BioRestorative Therapies?

The main programs are the Disc/Spine Program and the Metabolic Program, focusing on non-surgical treatment of lumbar disc disease and cell-based therapies for obesity and metabolic disorders, respectively.

What is BRTX-100?

BRTX-100 is a cell therapy product formulated from autologous cultured mesenchymal stem cells intended for the non-surgical treatment of chronic lumbar disc disease.

How does BRTX-100 work?

BRTX-100 involves injecting cultured stem cells into a patient’s damaged disc to alleviate pain caused by protruding and bulging lumbar discs.

What recent partnership has BioRestorative Therapies entered into?

BioRestorative Therapies has signed a five-year exclusive supply agreement with Cartessa Aesthetics to bring cell-based innovations to the aesthetics market.

How financially stable is BioRestorative Therapies?

BioRestorative ended 2023 with approximately $11.1 million in cash and cash equivalents, supplemented by $7.6 million from a private placement.

What are the potential benefits of the partnership with Cartessa Aesthetics?

The partnership aims to commercialize proprietary cell-based products in the aesthetics market, potentially generating significant revenue for BioRestorative.

What is the focus of BioRestorative's Metabolic Program?

The Metabolic Program focuses on developing cell-based therapies for obesity and metabolic disorders using brown adipose-derived stem cells.

Who can I contact for investor relations at BioRestorative Therapies?

You can contact Investor Relations at BioRestorative Therapies by emailing ir@biorestorative.com.

Where can I find more information about BioRestorative Therapies?

More information can be found on their website at www.biorestorative.com.

BioRestorative Therapies, Inc.

Nasdaq:BRTX

BRTX Rankings

BRTX Stock Data

9.94M
5.08M
26.61%
13.74%
1.08%
Biotechnology
Services-misc Health & Allied Services, Nec
Link
United States of America
MELVILLE